CAMELOT study

Introduction

Design:

• 1991 patients with angiographically significant coronary artery disease (> 20% stenosis)
• diastolic blood pressure < 100 mm Hg
• mean BP = 129/78

Exclusion criteria:

• left main coronary artery stenosis > 50%
• LV ejection fraction < 40%
• moderate-severe heart failure
• use of antihypertensive other than amlodipine or enalapril

Treatment:

• amlodipine 10 mg QD
• enalpril 20 mg QD
• placebo

Duration: 24 months

Results:

• patients receiving amlodipine less likely to experience adverse cardiac events* than placebo group (RR 0.69)
• non-significant risk reduction for amlopidine vs enalapril (RR 0.81) & enalapril vs placebo (RR 0.85)
• both amlodipine & enalapril diminished mean BP by 5/3 mm Hg

* revascularization

hospitalization for

• angina pectoris
• myocardial infarction
• stroke

Study sponsored by manufacturer of amlodipine

More general terms

• clinical trial

Additional terms

• antihypertensive agent
• coronary artery disease; coronary atherosclerosis (CAD)